About Us

Enteris BioPharma Inc., a wholly-owned subsidiary of SWK Holdings Corp. (SWKH), is a fully integrated development and manufacturing organization offering innovative oral drug delivery solutions.

Since its founding in 2013, Enteris has adapted its oral drug delivery technology to advance multiple internal and client programs into the clinic. Unlike other technologies, Peptelligence® and ProPerma® uniquely address issues with both solubility and permeability in a solid oral dosage form, enabling new and highly scalable treatment opportunities for compounds that typically need to be injected.

More recently, with the financial support of SWK Holdings Corp., Enteris has completed a renovation of its 32,000 square-foot GMP facility, including HPAPI containment, in Boonton, New Jersey, enabling long-term partnerships for challenging solid oral drug product development from preclinical through commercial cGMP manufacturing.

Enteris BioPharma picture showing two hands reaching out for a handshake.


Enteris BioPharma is led by a highly seasoned and innovative executive leadership team, spanning more than 75 years of collective pharmaceutical and biotechnology industry experience.